Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab versus placebo after bone radiotherapy in post-docetaxel castration-resistant prostate cancer
NL-OMON36426Phase 3Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in castration-resistant prostate cancer (CRPC) comparing Radiotherapy + ipilimumab with Radiotherapy + placebo (2 arms). Primary endpoint: Overall survival. Started Dec 2009; status: active, not recruiting.
02
Drugs
ipilimumab
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NL-OMON36426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36426.